Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.

Aaron S KellySilva ArslanianDan HesseAske Thorn IversenAntje KörnerSigne SchmidtRasmus SørrigDaniel WeghuberAnia M Jastreboff

Published in: Obesity (Silver Spring, Md.) (2023)

Semaglutide was highly effective in reducing BMI category. While on treatment, most trial participants' BMI improved by ≥1 category and > 40% reached a category below the obesity threshold. This article is protected by copyright. All rights reserved.

Keyphrases

weight gain
body mass index
insulin resistance
weight loss
metabolic syndrome
type diabetes
high fat diet induced
young adults
physical activity
study protocol
clinical trial
skeletal muscle
adipose tissue
phase iii
newly diagnosed
replacement therapy